The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
 
Niamh M. Keegan
Research Funding - Epic Sciences
 
Samantha E Vasselman
No Relationships to Disclose
 
Ethan Barnett
Stock and Other Ownership Interests - Biondvax; Gilead Sciences
 
Barbara Nweji
No Relationships to Disclose
 
Emily Carbone
No Relationships to Disclose
 
Alexander Blum
No Relationships to Disclose
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Advanced Accelerator Applications; Athenex; Bayer; Curium Pharma; Endocyte; Exelixis; Johnson & Johnson; Lantheus Medical Imaging; NCCN; Novartis; ORIC Pharmaceuticals; Progenics
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Janssen (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Endocyte; Fujifilm
 
Dana E. Rathkopf
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Janssen; Myovant Sciences
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Phosplatin Therapeutics (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Susan F. Slovin
Consulting or Advisory Role - Bayer; Clovis Oncology; Pfizer
Speakers' Bureau - OncLive; PER; Prime Oncology; Society for Immunotherapy of Cancer
Research Funding - AstraZeneca
 
Daniel Costin Danila
Honoraria - Angle; Astellas Pharma; AxImmune; Clovis Oncology; Pfizer; Pfizer
Consulting or Advisory Role - Angle; Astellas Pharma; AxImmune; Clovis Oncology; Pfizer; Sanador
Research Funding - Janssen Research & Development (Inst); Prostate Cancer Foundation
Patents, Royalties, Other Intellectual Property - GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER
Travel, Accommodations, Expenses - American Austrian Open Medical Institute; Astellas Pharma; Genzyme; Janssen Scientific Affairs; Pfizer; Prostate Cancer Foundation
 
Karen A. Autio
Research Funding - Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); Tizona Therapeutics, Inc. (Inst)
 
Howard I. Scher
Honoraria - Elsevier
Consulting or Advisory Role - Ambry Genetics/Konica Minolta; Amgen; Bayer; ESSA; Janssen; Janssen Research & Development; Menarini Silicon Biosystems; Pfizer; Sun Pharma; WIRB-Copernicus Group
Research Funding - Epic Sciences (Inst); Illumina (Inst); Janssen (Inst); Menarini Silicon Biosystems (Inst); Thermofisher Scientific Biomarkers (Inst)
Patents, Royalties, Other Intellectual Property - BioNTech -Intellectual Property Rights; Elucida Oncology - Intellectual Property Rights; MabVAX - Intellectual Property Rights; Y-mAbs Therapeutics, Inc - Intellectual Property Rights
Travel, Accommodations, Expenses - Bayer; ESSA; Konica Minolta; Menarini Silicon Biosystems; Phosplatin Therapeutics; Prostate Cancer Foundation; WIRB-Copernicus Group
 
Philip W. Kantoff
Employment - Convergent Therapeutics
Leadership - Context Therapeutics; Convergent Therapeutics; XLink
Stock and Other Ownership Interests - Cogent Biosciences; Context Therapeutics; Druggablity Technologies; Mirati Therapeutics; Placon; PrognomIQ; Seer; SynDevRx; XLink
Consulting or Advisory Role - Anji Pharma; Candel Therapeutics; Context Therapeutics; Druggablity Technologies; Genentech/Roche; Janssen; Merck; OncoCellMDX; Progenity; PrognomIQ; Seer; SynDevRx; Tarveda Therapeutics; Veru; XLink
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Other Relationship - Bayer (I)
 
Wassim Abida
Honoraria - Aptitude Health; Clinical Education Alliance; Medscape; OncLive/MJH Life Sciences; Roche
Consulting or Advisory Role - Clovis Oncology; Daiichi Sankyo; Janssen; ORIC Pharmaceuticals
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Epizyme (Inst); ORIC Pharmaceuticals (Inst); Zenith Epigenetics (Inst)
 
Konrad H. Stopsack
No Relationships to Disclose